Long-Acting Antiretrovirals: Where Are We now?

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges

(2016) Martina Kovarova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

(2016) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

(2016) Ian McGowan et al.   Lancet HIV

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa

(2016) Annalene Nel et al.   PLoS One

Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis

(2015) Manjula Gunawardana et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations

(2015) Pavan Puligujja et al.   BIOMATERIALS

The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy

(2015) Eric L. Ross et al.   CLINICAL INFECTIOUS DISEASES

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers

(2015) R Verloes et al.   HIV MEDICINE

Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy

(2015) Shilpa Viswanathan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

(2015) Kerri J. Penrose et al.   JOURNAL OF INFECTIOUS DISEASES

Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection

(2015) Rochelle P. Walensky et al.   JOURNAL OF INFECTIOUS DISEASES

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

(2015) J. Radzio et al.   Science Translational Medicine

Formulation and pharmacology of long-acting rilpivirine

(2015) Peter E. Williams et al.   Current Opinion in HIV and AIDS

A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women

(2014) Annalene Nel et al.   AIDS

Pharmacokinetics of Injectable, Long-Acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants

(2014) John M. Cortez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence

(2014) K. Rivet Amico et al.   CLINICAL INFECTIOUS DISEASES

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

(2014) Jean B. Nachega et al.   CLINICAL INFECTIOUS DISEASES

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

(2014) A G A Jackson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis for HIV in Young Men Who Have Sex with Men in NYC: A P18 Cohort Substudy

(2014) Kathrine Meyers et al.   PLoS One

Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

(2014) C. D. Andrews et al.   SCIENCE

Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals

(2013) Nikolas Wada et al.   AIDS

Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008

(2013) Nikolas Wada et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy

(2013) Nagsen Gautam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

(2013) Susan L. Ford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS

Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients

(2013) Jennifer Williams et al.   Nanomedicine

Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

(2013) Hasina Samji et al.   PLoS One

Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial

(2011) Aimee Wilkin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

State of the art of nanocrystals – Special features, production, nanotoxicology aspects and intracellular delivery

(2011) Rainer H. Müller et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Depression and HIV/AIDS Treatment Nonadherence: A Review and Meta-analysis

(2011) Jeffrey S Gonzalez et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

(2010) Frederick L Altice et al.   LANCET

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

(2010) T. Zhou et al.   SCIENCE

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY